Denosta 60 Mg Injection

Product Description

Introduction to Denosta 60mg Injection

Denosta 60mg injection consists of the active ingredient Denosumab. It is a medication used to treat osteoporosis, characterized by weakened bones. It is also prescribed to prevent bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases. Denosta 60mg injection works by inhibiting a protein called RANK ligand, which plays a role in the breakdown of bone tissue. Studies proved it can significantly increase bone density, reducing fracture risk in postmenopausal women with osteoporosis and patients with cancer-related bone loss. Close monitoring of renal function may be necessary for patients with moderate renal impairment.

Denosta 60mg injection should not be used in individuals with known hypersensitivity or allergic reactions to its components. Adequate calcium and vitamin D supplementation is required to ensure during the treatment. It is not approved for use in children and adolescents. Its safety and effectiveness in pediatric populations have not been established, so its use is contraindicated in individuals under 18. This medication should be used cautiously in individuals with pre-existing hypoparathyroidism, characterized by low parathyroid hormone levels.

Mechanism of Action

Denosta 60 Mg Injection features denosumab, a monoclonal antibody that inhibits the activity of RANKL, a protein responsible for bone breakdown. By blocking RANKL, Denosta slows bone loss and helps increase bone density, providing effective management for osteoporosis and bone loss due to cancer therapies.


Administration and Usage

Administer Denosta as a subcutaneous injection every six months, using the prefilled syringe provided. The injection should be given by a healthcare professional, after confirming normal calcium levels. Ensure that the solution remains clear to pale yellow, and do not use if discolored. Always follow storage instructions and keep the product refrigerated.


Safety and Monitoring

Prior to beginning Denosta therapy, monitor calcium levels, as the medication is contraindicated in those with hypocalcemia or hypersensitivity to denosumab. Common side effects include muscle pain, urinary tract infections, upper respiratory infections, and rash. Patients should report any adverse effects promptly to their physician.